Immune checkpoint inhibitors (ICIs) with atezolizumab plus bevacizumab are promising
agents for unresectable hepatocellular carcinoma (HCC). We tried to guide the treatment …

Aim This study aimed to investigate the utility of C-reactive protein (CRP) and alpha-
fetoprotein (AFP) in immunotherapy (CRAFITY) score in hepatocellular carcinoma (HCC) …

Background Since atezolizumab plus bevacizumab (ATE+ BEV) regimen for patients with
unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data …

Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first‐line
systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct …

Purpose: Atezolizumab+ bevacizumab is the new standard of care for systemic treatment-
naive, unresectable hepatocellular carcinoma (HCC). This exploratory study investigated on …

Simple Summary Hepatocellular carcinoma (HCC) is reportedly the fifth most common
malignancy in the world. Atezolizumab plus bevacizumab combination therapy (Atezo+ …

Simple Summary Although atezolizumab plus bevacizumab combination therapy was
approved in September 2020 as the first immune-combined therapy for hepatocellular …

Simple Summary The combination of atezolizumab and bevacizumab was introduced as a
first-line therapy for patients with unresectable hepatocellular carcinoma in 2020. Although …

Summary Alpha-fetoprotein (AFP) response (relative decline in AFP) is associated with
imaging response evaluated by response evaluation criteria in solid tumors ver1. 1 …

Simple Summary Immune checkpoint inhibitor therapy has been rapidly developed for the
treatment of unresectable hepatocellular carcinoma (HCC). In the IMbrave150 trial …